This is consistent with the clinical experience of the radiosensitivity displayed by high grade neuroendocrine cancers, driven by low expression of key DNA damage response enzymes, such as ATM and ATR36–38. The gene discussed is ATM; the disease is neuroendocrine carcinoma.